Online Exclusive

New Target Found in Mitochondria for Treatment of Blood Cancers

A recent study identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as AML.

FDA Alert

Approval for Polatuzumab Vedotin-Piiq for Diffuse Large B-Cell Lymphoma

The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adults with r/r DLBCL.

Your Career Path

How to Navigate Conferences & Make the Most of Your Time

Scientific conferences are vital to the growth of hematology/oncology and offer an avenue for researchers and clinicians in the field to share discoveries and enhance patient care.

2019 Great Debates & Updates in Hematologic Malignancies

Is MRD Ready for Prime Time in Multiple Myeloma?

Minimal residual disease (MRD) testing is not yet ready for prime time in multiple myeloma, according to a myeloma expert who convinced the audience to agree with him at the meeting.

Optimizing Dosing Regimens in Myeloma By Following Basic Principles of Therapy

By Mark L. Fuerst

Joseph R. Mikhael, MD, MEd, outlines 10 practice pearls that can assist the clinician in practically delivering myeloma therapies to patients. 

Sequencing Monotherapy Versus Combination Therapy in CLL

By Mark L. Fuerst

From the Issue

Adolescents and young adults with hematologic malignancies face a myriad of unique psychosocial issues that impact quality of life and milestones, including education, career and financial options, family planning, and establishing individual identity.

Colleague Conversations

Discussing the Evolution & Future of Treatment in Hematology/Oncology

HemOnc Times sat down with Pierluigi Porcu, MD, and Adam Binder, MD, both from Sidney Kimmel Cancer Center at Jefferson, to discuss the evolution of the field and recent advancements in various malignancies, including lymphoma and multiple myeloma.